BioPharm International-01-01-2002

BioPharm International

Outsourcing Outlook: E-Sourcing, Internet Facilitates Flexible Collaboration

January 15, 2002

Columns and Departments

15

1

by Jim Miller, BioPharmaceutical Outsourcing Report With Internet technologies, CROs can share risks, cut costs, and improve asset performance.

Inside Washington: Biotechnology in the Limelight, the Year Ahead

January 15, 2002

Columns and Departments

15

1

by Jill Wechsler Continued concerns about bioterrorism will shape legislative and regulatory initiatives affecting biotech manufactures.

Your Vested Interests: The War of the West

January 15, 2002

Columns and Departments

15

1

by Benjamin H. Rudolph and Viqar Aslam, Aptagen, Inc. One company shows the world that stem cell research isn't coing away -- and receives a worldwide ctroversy in the process.

Statistics for Laboratory Method Comparison Studies

January 15, 2002

Knowledge Architecture

15

1

by Robert T. Magari, Beckman Coulter Corporation In laboratory testing, you may want to use a new analytical method for measuring a chemical substance. To do so, you must be able to prove that the new method gives the same results as the previous one. Not all statistical methods for making laboratory comparisons are equally valid.

From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continues

January 15, 2002

Columns and Departments

15

1

by S. Anne Montgomery

Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation

January 15, 2002

Separation and Purification

15

1

by Naidong Weng and Timothy D.J. Halls, Covance Laboratories, Inc. Meeting the challenges of large-scale LC/MS/MS can improve the analytical processes that support biopharmaceutical drug development. The conclusion of this article presents troubleshooting techniques for LC/MS/MS and illustrates an automation strategy.

Liposomes (a Review): Part Two, Drug Delivery Systems

January 15, 2002

Knowledge Architecture

15

1

by Suggy S. Chrai, R. Murari, and Imran Ahmad Good manufacturing processes require that lipid vesicles be reproducibly uniform in size, carry the drug in sufficient concentration, and remain stable for an acceptable shelf-life under varying temperatures. Following these guidelines improves the analytical processes that support biopharmaceutical drug development.

Information Age Audits

January 15, 2002

Knowledge Architecture

15

1

by Joseph F. Noferi, Daniel E. Worden, and Edward R. Arling Understanding the reach of 21 CFR Part 11 is the first step to assessing its impact. To protect your company, you need integrated quality audit solutions to evaluate the underlying validation of your electronic data.

Considerations During Development of a Protein A-Based Antibody Purification Process

January 15, 2001

Separation and Purification

15

1

by Harish Iyer, Felicia Henderson, Eric Cunningham, James Welbb, John Hanson, Christopher Bork, and Lynn Conley, IDEC Pharmaceuticals Corporation Scale-up changes in an antibody purification process can increase final product purity, make the process more robust, and reduce processing time. This case study focuses on the initial purification step -- protein A chromatography -- and offers data collected from several years of process development work on many different antibodies.